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Abstract 
Although several studies have assessed the short-term effect of dietary supplements 
on the treatment and prevention of gastric ulceration in horses, few have assessed 
the response over a duration of more than 30 days. 
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A blinded randomised non-inferiority clinical trial was conducted using forty-two 
Thoroughbred horses in race training with squamous ulceration of ≥ grade 2/4, 
randomly assigned to one of two treatment groups for a period of 90 days: 
omeprazole at the full label dose of 4mg/kg or the Succeed® digestive conditioning 
supplement. Non-inferiority analyses and Wilcoxon sign rank tests were used to 
analyse the data. 
 
At day 90, Succeed® was non-inferior to 4mg/kg omeprazole administered daily in 
terms of the proportion of horses with complete resolution of squamous ulceration. 
At day 30, Succeed® was found to be inferior to omeprazole in terms of the 
proportion of horses with grade ≤1/4 squamous ulceration. The proportion of horses 
with reducing squamous ulcer score (compared with day 0) was statistically significant 
for both treatments at days 30 and 60. At day 90 of the 17 horses on Succeed®, nine 
had a reducing squamous ulcer score (p-value = 0.049) and of the 19 horses on 
omeprazole, 10 had a reducing squamous ulcer score at day 90 (p-value = 0.091). 
 
The non-inferiority of Succeed® compared to omeprazole at 90 days for the complete 
resolution of squamous ulceration and the reduced efficacy of omeprazole following 
90 days of treatment are likely to be of interest to practitioners managing gastric 
ulceration in performance horses. 
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1. Introduction 
The prevalence of squamous ulceration in racing Thoroughbreds has been reported as 
>70% in several studies [1–9]. Equine gastric ulcer syndrome (EGUS) is detrimental to 
horse health and performance due to associated pain and discomfort, [10,11]. 
Omeprazole, a proton pump inhibitor, is the most commonly used treatment for 
gastric ulceration in horses and is the only product licensed for this purpose in most 
countries. Omeprazole has been shown to be efficacious in the short term in four 
previous studies with healing rates of 73%-80% and improvement rates of up to 92% 
following 25-56 days of treatment [12–15]. The bioavailability of oral enteric coated 
omeprazole is variable but unaffected by feeding or fasting [16]. Withdrawal of 
omeprazole after 56 days of treatment has been reported as resulting in a rapid 
return of gastric ulceration [15]. However, another study showed only a 20% 
recurrence rate following withdrawal of omeprazole following 56days treatment [13].  
To the authors’ knowledge, the efficacy of omeprazole over a period of greater than 
60 days in horses maintained in race training has not been reported. 
 
Nutraceutical approaches for dealing with EGUS are being developed and tested. 
Hellings and Larsen (2014) [17] administered a mixture of B vitamins and salts of 
organic acids to performance horses presenting with EGUS for up to seven weeks and 
concluded that this may promote healing of gastric ulcers. A pectin and lecithin 
mixture, supplemented with an antacid reduced the severity of gastric ulceration over 
a 35-day period [18], but pectin – lecithin may be ineffective when given without an 
antacid [19]. A dietary supplement comprised of sea buckthorn berries reduced the 
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severity of glandular, but not squamous, ulceration in Thoroughbred horses [20].  
Sykes et al. (2013) [21] reported that a combination of pectin-lecithin complex 
(Apolectol®), live yeast and magnesium hydroxide, when supplemented for 24-27 
days reduced the severity of glandular and squamous gastric ulcers in Thoroughbred 
horses in race training. Andrews [22] reported that a supplement containing a 
number of ingredients, including pectin, lecithin, sea buckthorn and L-Glutamine may 
result in less severe recurrence of squamous ulceration following omeprazole 
treatment.  
 
Succeed® Digestive Conditioning Program® (Succeed®) is a daily supplement designed 
to support gastro-intestinal health of horses. Succeed® is a nutraceutical supplement 
containing oat oil rich in polar lipids, oat flour rich in oat Beta Glucan, L-Glutamine 
and L-Threonine and extracts of the cell wall of Saccharomyces cerevisiae, one 
containing beta glucan and the other a mannan oligosaccharide (MOS). Anecdotally, 
this product is used in the management of gastric ulceration. However, it has not 
previously been evaluated in a blinded clinical trial.  
 
The aim of the current study was to examine the hypothesis that Succeed® is not 
inferior to omeprazole for the treatment of squamous ulceration in horses in race 
training over the course of 90 days.  
 
2.  Materials and Methods 
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2.1  Study design 
A blinded randomised clinical trial was conducted to compare the efficacy of 4mg/kg 
orally administered omeprazole (Gastrogard™) 1  with a dietary supplement 
(Succeed®)2 for the management of squamous gastric ulceration over a period of 90 
days. A sample size calculation was conducted which determined that 28 horses in 
each group would be required to provide 80% power, assuming 90% efficacy of both 
treatments and that a 20% difference in efficacy is not clinically important.  Ethical 
approval for this trial was provided by Health Products Regulatory Authority (HPRA) in 
Ireland. To meet the trial inclusion criteria, horses had to be in full-time race training 
for a minimum period of two weeks, not receiving any dietary supplements or 
medication and being in good health, according to the veterinary surgeon and trainer 
at the time of initiation of the trial. Recruitment was from two racing yards in Ireland 
and all horses on each yard which met the inclusion criteria were subjected to 
gastroscopy. Both flat and National Hunt yards were included in this study to 
represent a broad spectrum of racehorses in the UK and Ireland. Within each yard the 
management of horses was standardised with regards to exercise, training and 
nutrition although owing to inherent differences in training regimens and timing 
within the respective seasons it was not possible to standardise management 
between the two yards.  No changes were instituted in the management of horses in 
either treatment group in response to a diagnosis of gastric ulceration.  
 
2.2. Gastroscopic examination 
                                                          
1 Merial Animal Health Ltd, Harlow UK 
2 Freedom Health LLC, Ohio, USA 
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Prior to gastroscopic examination the horses were fasted for 12 hours and water was 
removed one hour before the procedure. Horses were identified by means of 
microchip number. Prior to gastroscopic examination 0.5mg/kg xylazine 3  was 
administered intravenously with an additional 0.5mg/kg administered if adequate 
sedation was not achieved. Gastroscopy was performed using a 3m endoscope4; 
following nasogastric passage a standardised examination protocol was performed 
including insufflation of the stomach and flushing the mucosal surface with water 
[23]. The entire examination was recorded on video and saved with the horse’s 
microchip number as identification. The glandular mucosa was inadequately observed 
in the majority of horses. Consequently, further analysis of glandular lesions was not 
included in the study.  
 
2.3. Treatment allocation and repeat examination 
If grade ≥2/4 ulceration was present the horse was randomly allocated to one of two 
treatment groups. Randomisation was performed by drawing cards on each of which 
one of the two treatment groups was stated. Treatment group A received omeprazole 
at the recommended dose of 4mg/kg PO q24hrs for a 90-day period. Those in 
treatment group B received Succeed® at the manufacturer’s recommended dose of 
27g total dose PO q24hrs for 90 days. Treatment was administered in the morning, 
prior to feeding and work. Gastroscopy was repeated at 30-day intervals throughout 
the 90-day trial period, resulting in horses that completed the trial undergoing four 
examinations. It was recommended that horses that were racing during the trial had 
                                                          
3
 Chanazine- Chanelle UK, Hungerford, Berkshire, UK 
4
 Pentax VSB 2900- Pentax Medical, Slough, UK 
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omeprazole withheld for five days prior to each racing date, based on a British 
Horseracing Authority detection time of 72 hours (3 days), with an additional safety 
margin added.5 Veterinary surgeons undertaking the gastroscopies, reviewing and 
assessing the videos and performing the statistical analysis were all blinded to 
treatment group, hence the study was triple blinded.  It was not possible to blind the 
trainer to treatment group due to differing appearance of the formulations of product 
and the need to withdraw omeprazole prior to racing.  
 
2.4.  Review of ulceration scores 
A panel of three Diplomates of either the European College of Equine Internal 
Medicine (ECEIM) or the American College of Veterinary Internal Medicine reviewed 
videos (authors HC, RC and DS). Each video was graded for both squamous and 
glandular ulceration; the median value of the three reviewers was used as the 
definitive ulcer grade. The grading system chosen was in accordance with the recent 
consensus statement from the ECEIM [24] (Table 1) due to the highest level of inter-
operator agreement [25]. Reviewers were also asked to state if they believed the 
video was non-diagnostic. If one reviewer stated a video to be non-diagnostic, the 
mean of the remaining two grades was used as the definitive grade. If more than one 
reviewer stated the video was non-diagnostic this video was removed from further 
analysis.   
 
                                                          
5
 Detection Times- British Horseracing Authority http://www.britishhorseracing.com/resources/equine-science-and-
welfare/medication-control.asp 
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2.5  Statistical analysis 
Inter-observer agreement was assessed for squamous ulceration using a weighted 
kappa, the kappa weighting is detailed in Table 2. The agreement between each pair 
of reviewers was assessed. Degrees of inter-observer agreement were as suggested 
by Landis and Koch [26]: κ <0.20= poor agreement, κ 0.21-0.40= fair agreement, κ 
0.41-0.60= moderate agreement, κ 0.61-0.80= substantial agreement, κ 0.81-1.00= 
excellent agreement.  
 
A Wilcoxon-rank sum test was performed to assess the difference in squamous 
ulceration scores, for both treatment groups, at day 0 of the trial. Non-inferiority was 
assessed using a one-sided upper 90% confidence interval of the difference in 
treatment failure percentage between the two treatment groups [27] for the healing 
of squamous gastric ulcers at each time point. Data are presented as the difference in 
treatments for each of the three measures of success (Omeprazole- Succeed®) with 
90% confidence intervals. A 20% difference in clinical outcome was defined as the 
point at which treatments would be considered different, this margin is based on a 
previous non-inferiority study in gastric ulceration in horses [28] which established 
the a priori non-inferiority margin of 20% based on similar human studies assessing 
gastrointestinal injury. For the purposes of non-inferiority analysis, three different 
measures of success were used:  
 Improvement of squamous mucosal grade by 2 or more since day 0 
 Squamous ulcer grade of 1/4 or less at the time point of interest 
 Complete resolution of ulceration (i.e. grade 0/4 at the time point of interest) 
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Wilcoxon sign rank tests were used to assess the change in squamous ulcer score 
(from day 0) for horses on the two treatments, at days 30, 60 and 90. Two 
commercially available statistical software packages were used (Minitab version 
12.1.26 and Stata version 13.17).   
 
3. Results 
Sixty-six horses underwent an initial gastroscopy; the retention of horses at various 
stages of the trial is described in Figure 1, showing the percentage of horses with 
squamous gastric ulceration of grade ≥2/4 from the initial group presented, and the 
percentage of horses remaining in each treatment group at each time point.  
 
Inter-observer agreement for grading of squamous gastric ulceration was found to be 
substantial [26] ranging from Κ=0.65 to Κ=0.73 for the three paired estimates of 
agreement between reviewers. At day zero there was no significant difference 
between treatment groups for squamous gastric ulcer score (P=0.29). The distribution 
of grades at day zero is shown in figure 2.  
 
Of the 36 horses with four diagnostic gastroscopies, 13 were from a flat racing yard, 
of which six horses received omeprazole and seven horses received Succeed®. There 
were 23 horses from a National Hunt yard, of which 12 received omeprazole and 11 
received Succeed®. One horse from the Succeed® group was not included in statistical 
analysis as all the gastroscopies from this horse were deemed to be non-diagnostic 
                                                          
6 Minitab Inc, USA, http://www.minitab.com 
7 StataCorp LP, College Station, Texas, USA. 
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due to the presence of gastric contents, suggesting this horse had delayed gastric 
emptying compared to its cohort.  Figure 3 shows the changes in grade for each 
treatment at each time point, a zero on the y-axis indicates no change in ulcer score 
from day 0. 
 
3.1  Non-inferiority analysis 
Non-inferiority analysis (Table 3 and Figure 4) showed that at day 90 Succeed® 
was non-inferior to omeprazole for complete resolution of squamous ulceration. At 
day 90 non-inferiority was close to being shown for an improvement in squamous 
ulcer score by two of more grades (upper 90% Confidence Interval = 20.4). At day 30 
Succeed® was shown to be inferior to omeprazole in terms of squamous ulcer grade 
one or less and close to inferior in terms of improvement by two or more grades 
(lower 90% Confidence Interval = 18.4). For all other measures of success and time 
points (improvement in squamous ulcer score by two or more grades at day 60; 
squamous ulcer grade one or less at days 60 and 90; complete resolution of 
squamous ulceration at days 30 and 60) non-inferiority analysis was inconclusive. 
 
3.2  Treatments efficacy 
The number of horses with a positive, negative or no change in squamous ulcer score 
from day 0 to day 30, 60 and 90, on each treatment is given in table 3. Both 
treatments showed statistically significantly greater numbers of horses with reducing 
squamous ulcer score (than increasing squamous ulcer score) at days 30 and 60. Of 
those horses on omeprazole 14 of 21 (66.7%) and 16 of 21 (76.2%) at days 30 and 60, 
respectively had a positive change in squamous ulcer score, from day 0. Of those 
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horses on Succeed® 9 of 20 (45%) and 11 of 19 (57.9%) at days 30 and 60, respectively 
had a positive change in squamous ulcer score, from day 0. The equivalent analysis for 
day 90 was more marginal: Of the 17 horses on Succeed®, nine had a reducing 
squamous ulcer score at day 90 (p-value = 0.049) and of the 19 horses on omeprazole, 
10 had a reducing squamous ulcer score at day 90 (p-value = 0.091). 
 
3.3  Withdrawal periods for horse on omeprazole 
Of 19 horses that completed the trial on omeprazole, 12 had withdrawal periods 
applied during the trial. Of these, one horse had one withdrawal, one horse had two 
withdrawals, four horses had three withdrawals, three horses had four withdrawals 
and three horses had five withdrawals. The mean total withdrawal period and longest 
consecutive withdrawal period during the 90 day trial was: for all horses on 
omeprazole - total 13days (range 0-38days), consecutive 4.6days (0-14days) and, 
those subject to withdrawal - total 18days (4-38days), consecutive 6.5days (4-14days). 
 
4.  Discussion 
The present study is the first to demonstrate that a nutraceutical supplement, that 
provides a number of ingredients targeted to support gastrointestinal health, is non-
inferior to omeprazole in terms of its ability to ameliorate squamous ulceration in the 
horse when provided in the diet for at least 90 days. When used at a dosage of 27g po 
q24hrs the Succeed® Digestive Conditioning Program® supplement was found to be 
non-inferior to 4mg/kg omeprazole administered q24hrs at the end of a 90 day course 
of treatment when complete resolution of ulceration was used as the measure of 
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success. Non-inferiority was close to being shown at day 90 for an improvement in 
squamous ulcer score by two or more grades. Figure 4 clearly shows a trend, 
regardless of the measure of success used, in that any difference in the efficacy of the 
two treatments reduces as duration of treatment increases, with non-inferiority 
achieved or almost achieved in two cases.  
 
Non-inferiority analysis has the advantage of providing a comprehensive measure of a 
difference between two treatments by including direction of effect and an estimation 
of whether this is of clinical significance by including a pre-defined margin of 
difference[27]. As such it is also interesting to note that for two measures of success, 
at day 30, Succeed® was inferior or almost inferior to omeprazole. Viewed together 
these analyses suggest that omeprazole is more efficacious in the short term (less 
than 60 days), but that by day 90 there is little, if any difference between the two 
treatments. Indeed compared with day 0, at days 30 and 60, significantly more horses 
showed a reducing rather than increasing squamous ulcer score on both treatments. 
However, at day 90 the equivalent analysis for omeprazole was no longer statistically 
significant (p-value = 0.091) whereas that for Succeed® remained (marginally) 
statistically significant (p-value = 0.049). The percentage of horses showing 
improvement on omeprazole compared with Succeed® was higher at days 30 and 60. 
But at day 90 there was no difference between the two treatments on this measure 
(52.6% of horses on omeprazole and 52.9% of horses on Succeed®). It is important to 
note that this study was not designed to measure the efficacy of each treatment per 
se and for that reason it is likely that these findings may in part be due to a lack of 
statistical power. 
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The findings relating to the efficacy of omeprazole at day 30, concur with previous 
work [13,14,29–31]. However, this is the first study, to the author’s knowledge that 
has identified a reduced efficacy of omeprazole after more than 2-months of 
treatment. This along with the finding of non-inferiority at day 90 for Succeed® 
compared with omeprazole raises the question of whether omeprazole continues to 
result in acid suppression over a prolonged period of time. However, there is very 
limited strong evidence of rebound acid hypersecretion in humans following cessation 
of treatment with proton pump inhibitors for periods of longer than eight weeks [32].  
It is possible that a rebound gastric acidosis occurs in horses subjected to intermittent 
withdrawal for reasons of competitive activity. In this study a mandatory withdrawal 
period of five days was applied to those in the omeprazole group prior to a racing 
commitment. This was not prevented as the investigators felt it was important to 
compare these two products in true ‘field conditions.’ Indeed, the authors believe 
that the maintenance of horses in full race training is an advantage in this study in 
order to reflect normal usage of both omeprazole and the dietary supplement. 
However, the authors also recognise that given more than half of the horses on 
omeprazole had at least one period of withdrawal of treatment at some point during 
the trial (indeed 10 of 21 horses had at least three withdrawal periods) it is likely that 
the reduced efficacy of omeprazole at day 90 is associated with these enforced 
withdrawals that were required to allow horses to race. The physiological mechanism 
associated with this reduced efficacy may be contended but the outcome of 
intermittent withdrawal has not previously been investigated and given the 
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prevalence of gastric ulceration in performance horses this would be a useful area to 
pursue. 
 
4.1 Limitations of the study 
It is also possible that the number of inconclusive findings is a result of the lower than 
expected efficacy of both treatments and with non-inferiority analysis there is a risk 
of declaring non-inferiority in error as a result of the investigational drug being less 
effective than was anticipated [33]. Further studies are required to investigate the 
effect of prolonged administration of omeprazole, especially as this drug is frequently 
administered to performance horses for the duration of an athletic season.  
 
The large number of inconclusive comparisons on the non-inferiority analysis may be 
due to a lack of statistical power. Although a sample size calculation was performed 
before commencement of the study, there were a higher number of horses lost from 
the study than was anticipated and the initial prevalence of gastric ulceration was 
lower than estimated.   
 
4.2  Conclusions 
To the author’s knowledge this is the first study to report the efficacy of treatments 
for gastric ulceration over a period of greater than two months. Succeed® was shown 
to be non-inferior to omeprazole following 90 days of treatment. Given the often-
prolonged use of treatments for gastric ulceration over a racing season, the authors 
believe this to be a notable finding. Additionally, the finding that prolonged 
administration of omeprazole did not result in a statistically significant resolution of 
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squamous ulceration warrants further investigations which also account for periods of 
withdrawal.  
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Table 1: Grading system for equine squamous gastric disease (adapted from the 
1999 EGUS Council scoring system) [24] 
Grade of Ulcer Description of lesion 
0 The epithelium is intact and there is no appearance of hyperaemia 
(reddening) or hyperkeratosis (yellow appearance to the squamous 
mucosa) 
1 The mucosa is intact, but there are areas of reddening or 
hyperkeratosis (squamous) 
2 Small, single, or multifocal lesions 
3 Large, single, or multifocal lesions or extensive superficial lesions 
4 Extensive lesions with areas of apparent deep ulceration 
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Table 2. Weighting matrix used to calculate paired weighted kappa statistics 
  Clinician 1 
Grade of 
ulceration 
0 1 2 3 4 
Clinician 2 
0 1 0.8 0.4 0 0 
1 - 1 0.8 0.4 0 
2 - - 1 0.8 0.4 
3 - - - 1 0.8 
4 - - - - 1 
 
 
 
Table 3. Non inferiority analysis of the effect of Succeed® digestive conditioning 
supplement, compared to omeprazole in the healing of squamous ulceration. 
Measure of 
success 
Day Treatment group Succeed® Treatment group omeprazole Difference in % success 
(Omeprazole - 
Succeed®) 
90% CI (Lower-
Upper) 
 % Success (number with successful outcome/Number of horses) 
Improvement 
by two or more 
grades 
30 5(1/20) 43(9/21) 37.9 (18.4-57.3) 
60 21(4/19) 33.3(7/21) 12.3 (-10.6-35.1) 
90 23.5(4/17) 21(4/19) -2.5 (-25.3-20.4) 
Squamous 
grade of ≤ 1 
30 10(2/20) 52.4(11/21) 42.4 (21.3-63.4) 
60 31.6(6/19) 52.4(11/21) 20.8 (-4.3-45.9) 
90 23.5(4/17) 26.3(5/19) 2.8 (-20.9-26.5) 
Complete 
resolution of 
squamous 
pathology 
30 0 (0/20) 28.8(6/21) 28.6 (12.4-44.8) 
60 15.8(3/19) 19(4/21) 3.3 (-16.4-23.0) 
90 17.6 (3/17) 10.6 (2/19) -7.1 (-26.2-12.0) 
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Table 4. The number of horses in each treatment group, at each time point, that 
showed a positive change (i.e. improving), negative change (i.e. worsening) or no 
change in squamous ulcer score from day 0. 
 Change in squamous ulcer score (positive, negative or no change from day 
0) on Succeed® or omeprazole at the three different time points 
Day 30 Day 60 Day 90 
Succeed® 
(n=20) 
Omeprazole 
(n=21) 
Succeed®
(n=19) 
Omeprazole 
(n=21) 
Succeed® 
(n=17) 
Omeprazole 
(n=19) 
Positive (i.e. 
reducing 
squamous 
ulcer score) 
9 14 11 16 9 10 
Negative (i.e. 
increasing 
squamous 
ulcer score) 
2 2 2 2 3 4 
No change in 
squamous 
ulcer score 
9 5 6 3 5 5 
Wilcoxon 
sign rank test 
p-value 
0.032 0.003 0.009 0.001 0.049 0.091 
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Figure 1. Flow chart showing the number of horses at each stage of the trial. 
 
Figure 2. Bubble plot showing the distribution of grades at day 0. (Note that although 21 horses were 
assigned to the Succeed® group, grades were available from only 20 horses as one horse had 
gastroscopies deemed to be non-diagnostic, on review, throughout the trial period). 
 
Figure 3. Bubble plot showing the number of horses in each treatment group with four diagnostic 
gastroscopies representing each change in squamous ulcer grade over time; the size of the bubble is 
reflective of the number of horses in each group with a squamous ulcer score which changed by the 
number of grades on the y axis. 
 
Figure 4. Treatment differences for different measures of success with 90% confidence intervals shown. 
The clinically significant treatment difference of 20% is marked by a dashed line. When the 90% 
confidence interval crosses this dashed line the result is inconclusive for non-inferiority. When the upper 
90% confidence limit is below the dashed line the experimental treatment (i.e. Succeed®) is non-inferior 
to omeprazole. When the lower 90% confidence limit is above the dashed line the experimental 
treatment (i.e. Succeed®) is inferior to omeprazole. 
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